Background: Obesity is a major risk factor for
INTRODUCTION
Cardiovascular disease (CVD) is the leading cause of death in the US, accounting for over one-third of all deaths in 2007 [1] . By the year 2030, it is projected that over 40% of the US population will have some form of CVD [2] . Obesity, reported to affect 34% of the US adult population [3] , is a major risk factor for CVD that may exacerbate other known CVD risk factors, such as hypertension, dyslipidemia, and diabetes [1, 4] . Weight loss improves these risk factors [5] [6] [7] [8] with the degree of improvement often commensurate with the degree of weight loss [5, 9] . Bariatric surgery complemented by lifestyle modification is associated with gradual and sustained weight loss and has become a viable weight management approach in select patients [7, [10] [11] [12] , with some guidelines including laparoscopic adjustable gastric banding (LAGB) for individuals with body mass index (BMI) C30 and 1 or more comorbidities of obesity [10] . Although surgery-facilitated weight loss typically improves CVD risk factors [7, 13] , the longterm clinical impact of the weight loss on CVD risk factors and on outcomes after bariatric surgery is not well described.
Cardiovascular disease risk algorithms, including those developed within the
Framingham Heart Study (FHS) [14] [15] [16] , may inform predicted clinical impact of obesity and weight loss. Framingham Risk Scores (FRS) for 10-year coronary heart disease (CHD) are greater with BMI [17] and several studies have documented substantial reductions in 10-year CHD risk 1 year after bariatric surgery [18] [19] [20] [21] [22] ; however, these studies have not included LAGB. Notably, significant reductions in FRS have not been observed following pharmacologic or lifestyle weight loss interventions [23] .
The authors examined whether weight loss in LAGB-treated obese patients would be associated with meaningful reductions in 10- 
METHODS
The analysis in this article is based on previously collected data and does not involve any new studies of human or animal subjects performed by any of the authors. This study utilized data from a national network of outpatient offices, the Medical Quality Improvement Consortium (MQIC), using the (Fig. 2) .
Subgroup Analyses
Changes in CVD risk factors and scores were evaluated for subgroups stratified by gender and baseline BMI (Fig. 3) . The consistency of observed CVD risk reduction using lipid-based algorithms among the subset with lipid data strengthens results, as this algorithm was not based on changes in BMI.
However, a limitation of the study was the small sample with lipid data available and it is noted that the predicted CVD risk was higher for the office-based algorithms. These findings are substantiated by recent results from the Swedish Obese Subjects study, a prospective, non-randomized study of obese patients treated with either bariatric surgery (19% with banding) or non-surgical intervention with median follow-up of 14.7 years. Among bariatric surgery patients, risk of total and fatal CV events was reduced by 33 and 53%, respectively, as compared with control patients after adjusting for baseline conditions [24] . In addition, a recent systematic review and meta-analysis of studies reporting long-term mortality in morbid obesity among bariatric surgery patients reported significant reduced overall mortality in three studies and borderline reduced CVD mortality among two studies reviewed for LAGB procedure [25] . Previous studies have demonstrated an association between increasing BMI and both overall and CVDspecific mortality [26] [27] [28] , and weight loss has been consistently demonstrated to improve CVD risk factors, including hypertension, type 2 diabetes, and dyslipidemia [29] [30] [31] [32] [33] . In addition to improving CVD risk factors for individuals with comorbidities at time of intervention, weight loss is also associated with reduced risk of developing type 2 diabetes (58-88% risk reduction) [7, 32] , low HDL cholesterol (43-79% risk reduction) [7] , hypertension (45% risk reduction) [9] , hypertriglyceridemia (49-71% risk reduction) [7] , metabolic syndrome (41% risk reduction) [30] , and stroke (22% risk reduction) [34] .
Significant weight loss after bariatric surgery is accompanied by substantial reductions in CVD risk factors [7] [8] [9] 35] and overall mortality [7, 36] . Previous studies following other bariatric surgical procedures have also demonstrated significant reductions in predicted risk of CHD using FRS [19] . Obese patients who receive bariatric surgery experience an overall decrease in Framingham 10-year CHD risk score of 2.0-3.5 points [20] [21] [22] . In comparison, a study examining Framingham CVD risk following lifestyle and pharmacological intervention with orlistat did not report significant reduction in predicted CVD risk at 1 year of follow-up [23] . The present report is distinguished from and adds to previous investigations in terms of three significant approaches: (1) use of general CVD algorithms (including stroke and peripheral artery disease) rather than the more limited CHD algorithm, (2) Furthermore, adverse events due to the LAGB procedure were not included in the analysis.
Framingham CVD risk scores have not been validated for measuring changes in CVD risk over time or specifically in obese populations; however, in the present analysis scores based on BMI versus lipid data indicate similar and consistent magnitude of risk reduction. In addition, patients older than 59 years were included and the estimation procedure for 30-year CVD risk algorithm was developed on a sample aged 20-59 years [15] .
The predicted risk reductions assume patients would maintain the weight loss and improvements in risk factors over time; however, without longer-term follow-up, the authors cannot confirm this would be the case.
However, several studies have demonstrated long-term weight loss maintenance among LAGB treated patients 4-12 years after the procedure [11, 12] .
CONCLUSION
In conclusion, data from a large US healthcare database show patients receiving LAGB to have significant weight loss, and reduced CVD risk factors and estimated CVD risk, supporting the effectiveness of the LAGB procedure as a potential approach for management of obesity.
These results add to the evidence of the cardiovascular benefits of significant weight loss among obese individuals and the potential long-term clinical impact of the LAGB procedure as a therapeutic intervention for obesity. Larger and long-term studies are needed to further document whether effects of LAGB on weight loss and CVD risk factors translate into reduced CVD incidence.
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